Lexaria to Highlight its DehydraTECHTM Technol

Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences


DECEMBER 07, 2020 6:45AM EST

-Benzinga Global Small Cap Conference on December 8th
-LD Micro Main Event on Dec 15th
-H.C. Wainwright BioConnect, held on Jan 11-14
-Virtual Biotech Showcase, held on Jan 11-14

KELOWNA, BC / ACCESSWIRE / December 7, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria" , a global innovator in drug delivery platforms, announced today that its Chairman & CEO Chris Bunka is scheduled to present at four upcoming investor conferences in December 2020 and January 2021. The Company will discuss its recent successful testing of DehydraTECHTM that showed improved delivery of two classes of drugs currently in use against HIV/AIDS with potential for use against SARS-CoV-2/COVID-19.

Event: Benzinga Global Small Cap Conference

Date: Tuesday December 8, 2020

Time: 3:45 PM ET

Registration: https://events.benzinga.com/registration-page...bQQAvD_BwE

Event: LD Micro Main Event

Date: Dec 15, 2020

Time: 11 AM ET

Registration: https://ve.mysequire.com/
Event: H.C. Wainwright BioConnect
Date: Jan 11-14, 2021

Registration: https://hcwevents.com/bioconnect/

Event: Virtual Biotech Showcase

Date: Jan 11-14, 2021

Registration: https://informaconnect.com/biotech-showcase/

Mr. Bunka will provide an overview on the Company's proprietary drug delivery technology, DehydraTECH™ as well as planned initiatives to enhance the Company's focus on solutions related to the regulated pharmaceutical and medical market segments in 2021. He will also discuss the Company's recent sale of its non-core assets in preparation for uplisting to a national securities exchange.

About Lexaria

Lexaria Bioscience Corp.'s (OTCQX:LXRP)(CSE:LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.


INVESTOR CONTACT:

ir@lexariabioscience.com

Phone: 866-221-3341


Read More: https://investorshangout.com/post/view?id=598...z6fwxXegKQ